成大生物：拟共同投资设立成大生物医药产业投资基金

Group 1 - The company, Chengda Biological, announced the establishment of a biomedical industry investment fund in collaboration with its controlling shareholder, Liaoning Chengda, and its subsidiaries, aiming to enhance its competitive edge and capitalize on opportunities in the biopharmaceutical industry [1][2] - The total scale of the fund is set to not exceed 100 million yuan, with an initial size of 50.2 million yuan. The fund will be managed by Chengda Coastal, which will contribute 1 million yuan, representing approximately 0.1992% of the initial fund size [1] - Chengda Biological plans to contribute 40 million yuan, accounting for about 79.6813% of the initial fund size, while Liaoning Chengda will contribute 10 million yuan, representing approximately 19.9203% [1] Group 2 - The fund will focus on investments in the life and health sector during its investment period, with further capital contributions expected to reach the total commitment of 100 million yuan within three years [2] - The fund is currently in the planning stage, and the partnership agreement has not yet been formally signed, meaning that the investment shares are subject to the final agreement [2] - The company's board of directors has proposed to authorize the management to handle all matters related to this external investment, including timely progress on the fund's establishment and registration [2]